Latest Observability News

Transurban Group reveals modest investor uptake in its latest Distribution Reinvestment Plan, with new securities priced at $13.89 and set for issuance in February.

Patagonia Lithium has advanced drilling at its Formentera lithium project in Argentina to 308 metres, revealing encouraging porosity and brine characteristics that suggest strong lithium potential. Six successful packer tests indicate increasing brine concentration and flow rates, with further drilling planned to deepen the resource understanding.

AngloGold Ashanti has begun exploration drilling on Matsa Resources’ Lake Carey tenement, signalling strong interest in the region and setting the stage for 2026 exploration activities.

Strickland Metals has announced a $55 million institutional placement to fund an expanded drilling program and advance a Pre-Feasibility Study for its Rogozna gold project in Serbia, with major shareholders reaffirming their support.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

FMR Resources has extended its latest diamond drillhole at the Llahuin Project’s Target C, intersecting visual copper and molybdenum mineralisation linked to a key geophysical anomaly. This marks a promising step towards pinpointing the core of a significant porphyry copper-gold-molybdenum system.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

FMR Resources has extended its second diamond drillhole at the Southern Porphyry target within the Llahuin Project JV in Chile, uncovering visual copper and molybdenite mineralisation linked to a key geophysical anomaly. This advancement sharpens the focus on the core of a significant porphyry system.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.

Argenica Therapeutics has won a crucial regulatory waiver from the European Medicines Agency, removing the need for paediatric trials for its stroke drug ARG-007 and clearing the way for faster adult market approval in Europe.

Arika Resources has agreed to acquire the remaining 20% stake in its flagship Yundamindra and Kookynie gold projects, consolidating full ownership and positioning itself for accelerated exploration in Western Australia’s prolific goldfields.